Farani Priscila Silva Grijó, Jones Kathryn Marie, Poveda Cristina
Department of Biological Sciences, Border Biomedical Research Center, University of Texas at El Paso, El Paso, TX 79902, USA.
Department of Pediatrics, Division of Tropical Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
Vaccines (Basel). 2024 Aug 1;12(8):870. doi: 10.3390/vaccines12080870.
Chagas disease (CD) treatment and vaccine development are critical due to the significant health burden caused by the disease, especially in Latin America. Current treatments include benznidazole and nifurtimox, which are most effective in the acute phase of the disease but less so in the chronic phase, often with significant side effects. Here, using the available literature, we summarize the progress in vaccine development and new treatments that promise to reduce CD incidence and improve the quality of life for those at risk, particularly in endemic regions. New treatment options, such as posaconazole and fexinidazole, are being explored to improve efficacy and reduce adverse effects. Vaccine development for CD remains a high priority. The complex life stages and genetic diversity of present challenges, but several promising vaccine candidates are under investigation. These efforts focus on stimulating a protective immune response through various innovative approaches.
恰加斯病（CD）的治疗和疫苗研发至关重要，因为该疾病造成了巨大的健康负担，尤其是在拉丁美洲。目前的治疗方法包括苯硝唑和硝呋替莫，它们在疾病急性期最为有效，但在慢性期效果较差，且常常伴有严重的副作用。在此，我们利用现有文献总结了疫苗研发和新治疗方法方面取得的进展，这些进展有望降低恰加斯病的发病率，并改善高危人群（尤其是流行地区人群）的生活质量。正在探索新的治疗选择，如泊沙康唑和非昔硝唑，以提高疗效并减少不良反应。恰加斯病的疫苗研发仍然是重中之重。病原体复杂的生命阶段和基因多样性带来了挑战，但有几种很有前景的候选疫苗正在研究中。这些努力聚焦于通过各种创新方法激发保护性免疫反应。
